GT Biopharma, Inc. (GTBP) Cash Flow Statement
GT Biopharma, Inc. (GTBP) generated -$14.4M of operating cash flow over the twelve months to 2026-06-30, spent -$1.5M on capital expenditure and had free cash flow of -$12.9M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GTBPGT Biopharma, Inc.Follow GTBP — free
—
Price chart with a free account
- Market cap
- 9.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -1.0 | -1.0 | -0.4 | -1.7 | -4.7 | -1.9 | -5.4 | -10.7 | -3.7 | -7.3 | -15.6 | -15.2 | -8.9 | -12.9 | -12.9 | -14.4 | |
| Capital expenditure | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | 0.0 | 0.0 | 1.5 | |
| Free cash flow | — | -1.0 | -0.4 | -1.8 | -4.7 | -1.9 | -5.4 | -10.7 | -3.7 | — | — | — | — | -12.9 | -12.9 | -12.9 | |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.2 | — | |
| Stock-based compensation | 0.3 | 0.9 | 0.2 | 2.6 | 3.8 | 6.6 | 130.1 | 9.7 | 5.3 | 0.3 | 33.9 | 7.7 | — | 0.2 | 0.4 | — |
USD millions · SEC XBRL
GT Biopharma, Inc. — questions
- What is GT Biopharma, Inc.'s operating cash flow?
- -$14.4M over the twelve months to 2026-06-30.
- How much does GT Biopharma, Inc. spend on capital expenditure?
- -$1.5M over the twelve months to 2026-06-30.
- What is GT Biopharma, Inc.'s free cash flow?
- -$12.9M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from GT Biopharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.